Skip to main content

Day: March 12, 2025

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos EventsReported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025. Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives.Cash Guidance Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated...

Continue reading

Kalaris and AlloVir Announce Stockholder Approval of Merger

Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger,...

Continue reading

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About...

Continue reading

CAISSE FRANCAISE DE FINANCEMENT LOCAL EMTN 2025-6

Paris, 12 March 2025 Capitalised terms used herein shall have the meaning specified for such terms in the Caisse Française de Financement Local base prospectus to the €75,000,000,000 Euro Medium Term Note Programme dated 8 July 2024 (the “Base Prospectus”). Caisse Française de Financement Local has decided to issue on 14 March 2025 – Euro 54,000,000 Callable Fixed Rate Obligations Foncières due 14 March 2050. The Base Prospectus dated 8 July 2024 and the supplements to the Base Prospectus dated 13 September 2024, 30 September 2024, 26 December 2024 and 27 February 2025 approved by the Autorité des Marchés Financiers are available on the website of the Issuer (https://www.caissefrancaisedefinancementlocal.fr/), at the registered office of the Issuer: 112-114, avenue Emile Zola, 75015 Paris, France, and at the office of the Paying Agent...

Continue reading

AMG Critical Materials N.V. Successfully Repurchases 40% Stake in its Subsidiary Graphit Kropfmühl

Amsterdam, 12 March 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to confirm the transaction initially announced on December 23, 2024 to repurchase a 40% ownership interest in Graphit Kropfmühl GmbH, owned by an affiliate of Alterna Capital Partners, has been successfully completed as of March 12, 2025 in accordance with the announced terms. About AMG AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO2 in aerospace engines, as well as critical materials addressing CO2 reduction in a variety of other end use markets. AMG’s...

Continue reading

AMG Critical Materials N.V. Publishes 2024 Annual Report

Amsterdam, 12 March 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has published its 2024 Annual Report. The 2024 Annual Report is available to investors and other interested parties via the AMG website (www.amg-nv.com). Hard copies of the 2024 Annual Report can be requested by contacting AMG via email at info@amg-nv.com. About AMG AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO2 in aerospace engines, as well as critical materials addressing CO2 reduction in a variety of other end use markets. AMG’s...

Continue reading

Societe Generale: Renewals and appointments of board members proposed to the General Meeting to be held on 20 May 2025

RENEWALS AND APPOINTMENTS OF BOARD MEMBERS PROPOSED TO THE GENERAL MEETING TO BE HELD ON 20 MAY 2025  Press release  Paris, 12 March 2025 The Board of Directors of Societe Generale, upon the proposal of the Nomination and Corporate Governance Committee, approved the proposed renewals and appointments of board members ahead of the Shareholders’ General Meeting to be held on 20 May 2025. The Board of Directors invites the General Meeting to be held on 20 May 2025 to vote to replace two female directors (Mrs Lubomira Rochet, resigning since 12 September 2024, and Mrs Alexandra Schaapveld, end of her third term as an independent director) and to renew three male directors (Mr. William Connelly, Mr. Henri Poupart-Lafarge and Mr. Sébastien Wetter). Mrs Ingrid-Helen Arnold will be proposed for her first term as an independent Director. Aged 56...

Continue reading

Societe Generale: availability of the 2025 Universal Registration Document with the annual financial report

AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENT WITH THE ANNUAL FINANCIAL REPORT  Regulated Information Paris, 12 March 2025 Societe Generale hereby informs the public that the French version of the 2025 Universal Registration Document was filed with the French Financial Markets Authority (AMF) on 12 March 2025. The 2025 Universal Registration Document includes the 2024 annual financial report which is made up of notably: •         the sustainability report, in accordance with the transposition into French law of Directive (EU) 2022/2464 of 14 December 2022, commonly known as the Corporate Sustainable Reporting Directive (CSRD) and with Commission Delegated Regulation (EU) 2023/2772 of 31 July 2023 setting out the sustainability reporting standards (European Sustainability Reporting Standards, commonly referred to as “ESRS”); •...

Continue reading

Societe Generale: Availability of the 2025 Universal Registration Document with the annual financial report

AVAILABILITY OF THE 2025 UNIVERSAL REGISTRATION DOCUMENT WITH THE ANNUAL FINANCIAL REPORT  Regulated Information Paris, 12 March 2025 Societe Generale hereby informs the public that the French version of the 2025 Universal Registration Document was filed with the French Financial Markets Authority (AMF) on 12 March 2025. The 2025 Universal Registration Document includes the 2024 annual financial report which is made up of notably: •         the sustainability report, in accordance with the transposition into French law of Directive (EU) 2022/2464 of 14 December 2022, commonly known as the Corporate Sustainable Reporting Directive (CSRD) and with Commission Delegated Regulation (EU) 2023/2772 of 31 July 2023 setting out the sustainability reporting standards (European Sustainability Reporting Standards, commonly referred to as “ESRS”); •...

Continue reading

WRAP Appoints Jared Novick as President, Unveils Federal Support Plans to Enhance Efficiency and Productivity in Public Safety

U.S. Government efficiency initiatives unlock opportunities for WRAP to lead public safety tech consolidation, deliver cost savings and reform training solutions NORTON, Va., March 12, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“Wrap” or, the “Company”) is pleased to announce the promotion of Jared Novick to President and Chief Operating Officer of the Company. Under his leadership, Wrap expects to launch a new wave of efficiency-driven public safety offerings designed to support law enforcement and federal agencies. This expansion aligns with Wrap’s recent relocation of its manufacturing headquarters to Virginia, a move recognized by Virginia Governor Glenn Youngkin in November 2024. With plans to establish offices near Washington, D.C., the new location strengthens Wrap’s pursuit of U.S. Federal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.